<DOC>
	<DOCNO>NCT02412332</DOCNO>
	<brief_summary>The purpose study determine whether cell therapy autologous adult stem cell ( bone marrow and/or fat ) safe treatment advance Chronic Obstructive Pulmonary Disease ( COPD ) .</brief_summary>
	<brief_title>Cell Therapy Advanced Chronic Obstructive Pulmonary Disease Patients</brief_title>
	<detailed_description>Pulmonary emphysema , within spectrum Chronic Obstructive Pulmonary Disease ( COPD ) , describe destruction alveolar wall enlargement airspace distal terminal bronchiole , inflammatory infiltrate detectable fibrosis . Despite significant advance result introduction new therapeutic approach , pulmonary rehabilitation , effective palliative clinical treatment yet achieve . Surgical treatment , turn , involve highly complex procedure , case lung transplantation , shortage donor . In context , cell therapy stem cell present promising therapeutic alternative great potential applicability . The main goal study evaluate safety infusion bone marrow mononuclear cell ( BMMC ) , adipose-derived stem cell ( ASC ) , separately conjugate , COPD patient . The sample consist 20 advanced COPD patient ( grade 3 GOLD criterion ) . Patients , lot , divide four distinct group , namely : Group 1 : Control ; Group 2 : Bone marrow mononuclear cell ; Group 3 - Stem cell derive adipose tissue Group 4 : bone marrow mononuclear cell stem cell derive adipose tissue . After selection patient , clinical laboratory evaluation conduct ( cardiology , laboratory examination test define score dyspnea ) . The cell use cell therapy obtain patient 's bone marrow adipose tissue ( autologous ) . The separation bone marrow mononuclear ( BMMC ) perform centrifugation density gradient ( Ficoll ) , stem cell derive adipose tissue isolate enzymatic digestion ( collagenase ) cultivation . The infusion perform peripheral vein ( brachial ) preparation , separation , expansion quality control cell . The patient follow period 12 month . It expect clinical protocol allow expansion knowledge cell therapy pulmonary disease represent significant step towards establishment new therapeutic approach COPD treatment .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>COPD patient persistent dyspnea stage 2 3 dyspnea scale score ; Eligibility pulmonary rehabilitation program ; No smoke smoke cessation least 6 month . Absence emphysema chest tomography ; Pulmonary extrapulmonary infection active infection history le 3 month ; History coronary artery disease and/or severe ventricular dysfunction ( ejection fraction &lt; 55 % ) ; Presence pulmonary hypertension , ie , estimate systolic pulmonary artery pressure 35 mmHg transthoracic Doppler echocardiography ; Patients home oxygen therapy ; Advanced renal failure ( serum creatinine great 1.5 mg / dL ) liver failure CHILD B C ; Immunosuppressive infectious disease detect ; Patients know malignancy collagen disease ; Psychosocial problem , drug and/or alcohol abuse obedient establish medical protocol ; No family acceptance ; Pregnancy risk pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>advanced COPD ( stage III )</keyword>
	<keyword>Adult stem cell</keyword>
	<keyword>Cell therapy</keyword>
</DOC>